AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. Our mission is to make the heart stronger safely.
Heart failure (HF) affects more than six million individuals in the US and nearly 100 million worldwide, causing poor quality of life, recurrent hospitalizations, and a high risk of death. HF is a progressive cardiac syndrome, and it impairs ventricles’ ability to fill with or eject blood. The most common and serious form is HF with reduced ejection fraction, where contractility is reduced, leading to impaired delivery of blood and oxygen to organs and tissues.
Existing oral therapy delays progression and reduces hospitalization and death but no treatment targets impaired contractility – the underlying cause
Intravenous “inotropes” increase cardiac output to maintain organ function for hours-days, but cause ischemia, arrhythmia, hypotension, and increased mortality
AnaCardio is developing novel inotropic agents with a unique mode-of-action based on the ghrelin signalling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The agents increase cardiomyocyte contractility and force, leading to increased cardiac output which can potentially improve organ function, quality of life and functional capacity, and reduce the risk of hospitalization and death.
STOCKHOLM, Sweden, May 11, 2026 – AnaCardio today announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with
STOCKHOLM, Sweden, March 26, 2026 – AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure
Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and
Get in touch
Feel free to contact us if you have any questions or want to book a meeting.
Contact us
